• HOME
  • RECRUITMENT
    • WHY RECRUIT WITH US
    • PROVEN PROCESS
    • EXPERTISE AND EXPERIENCE
    • NETWORK OF CANDIDATES
    • EXECUTIVE RECRUITING
    • REQUEST MORE INFORMATION
    • SLONEXTRAS
  • ABOUT US
    • MISSION, VISION & VALUES
    • EXECUTIVE BIOS
    • ADVISORY BOARD
    • TESTIMONIALS
    • SLONE CARES
    • INDUSTRY INVOLVEMENT
  • SLONE NEWS
    • LATEST NEWS
    • PRESS RELEASES
    • NEWSLETTER
    • INDUSTRY HEADLINES
    • UPCOMING EVENTS
    • DIAGNOSTIC LABORATORY NEWS
  • CANDIDATES
  • FEATURED POSITIONS
  • COMPLETED SEARCHES
  • CONTACT US
Apycom jQuery Menus

Monthly Archives: March 2012

Post navigation

← Older posts

Report: DNA sequencing market will grow to $6.6 billion in five years

Posted on March 30, 2012 by Zach Helminiak at Slone Partners
Reply

The instruments and consumables market, along with workflow products, are expected to expand as well, although not at the same rate. Continue reading →

Posted in Genomics | Leave a reply

Researchers develop gene therapy treatment for hereditary blood disorders

Posted on March 28, 2012 by Zach Helminiak at Slone Partners
Reply

Both are genetic conditions and each have their own unique set of related health problems, including poor blood flow, organ damage and anemia. Continue reading →

Posted in Genomics | Leave a reply

Researchers develop advanced, noninvasive molecular imaging process

Posted on March 27, 2012 by Zach Helminiak at Slone Partners
Reply

Researchers have discovered a technique where nanoantennas are used in conjunction with artificial lipid membranes to witness billions of interactions between molecular structures. Continue reading →

Posted in Diagnostic Laboratory Industry | Leave a reply

Mice could serve as proxies for patients receiving new treatments

Posted on March 26, 2012 by Zach Helminiak at Slone Partners
Reply

Researchers will be able to rely on genetic patterns to hone in on the optimal care options for those who share genetic traits. Continue reading →

Posted in Anatomic Pathology | Leave a reply

Genetic testing spending expected to increase by five times in next decade

Posted on March 23, 2012 by Zach Helminiak at Slone Partners
Reply

More than half of consumers said they were are not entirely trusting of their physicians when it comes to administering, interpreting and protecting genetic information. Continue reading →

Posted in Genomics | Leave a reply

Negative side effects from drugs avoidable through personalized medicine

Posted on March 23, 2012 by Zach Helminiak at Slone Partners
Reply

Merck pulled its arthritis drug Vioxx from pharmacies in 2004 following increased concerns that the drug could increase the likelihood that a user would suffer a stroke or heart attack. Continue reading →

Posted in Personalized Medicine | Leave a reply

Autopsies drop to below 10 percent, leaving researchers with less data

Posted on March 20, 2012 by Zach Helminiak at Slone Partners
Reply

Medical professionals performed autopsies in cases involving disease only 4 percent of the time, which is especially problematic for researchers in the personalized medicine field. Continue reading →

Posted in Diagnostic Laboratory Industry | Leave a reply

Geneticist unexpectedly tracks own disease during personalized medicine study

Posted on March 19, 2012 by Zach Helminiak at Slone Partners
Reply

He told the news source that under normal circumstances, he might not have discovered he had diabetes until years later, after the condition worsened. Continue reading →

Posted in Genomics | Leave a reply

Genetic testing analysis, not sequencing, remains barrier to ideal treatments

Posted on March 14, 2012 by Zach Helminiak at Slone Partners
Reply

When the the twins’ mother did additional research regarding their symptoms, the Beerys decided to have their childrens’ genomes sequenced. Continue reading →

Posted in Genomics | Leave a reply

Will a genetic test ever cost as much as a standard blood test?

Posted on March 12, 2012 by Zach Helminiak at Slone Partners
Reply

Experts believe that as more genetic information and health outcomes are recorded from patients, exponential improvements in personalized medicine will follow. Continue reading →

Posted in Personalized Medicine | Leave a reply

Post navigation

← Older posts
Contact Us
Company Name:
* Contact Name:
* Contact Phone Number:
* Contact Email Address:
Comments:
CAPTCHA Image [ Different Image ]

Popular Posts

  • Landmark Case in the Supreme Court: Patenting the Human Genome
  • Negative side effects from drugs avoidable through personalized medicine
  • Report: DNA sequencing market will grow to $6.6 billion in five years
  • Kevin Krenitsky of Foundation Medicine
  • Three Reasons To Use a Recruitment Firm

Subscribe To Slone News

Last Name
email
 
     SLONEPARTNERS.COM © 2011